




Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study

Guowei Li^{1,2,6}, Xuhui Zhang^{3,6}, Yingxin Liu^{1,4}, Junguo Zhang¹, Likang Li¹, Xin Huang¹ ,
Lehana Thabane² and Gregory Y.H. Lip⁵

¹Center for Clinical Epidemiology and Methodology (CCEM), Guangdong Second Provincial General Hospital, Guangzhou, China. ²Dept of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada. ³Dept of Oncology No. 2, Guangdong Second Provincial General Hospital, Guangzhou, China. ⁴Dept of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China. ⁵Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK. ⁶These authors contributed equally to this work.

Corresponding author: Guowei Li (lig28@mcmaster.ca)



Shareable abstract (@ERSpublications)

Regular use of glucosamine was significantly related with a 16% lower risk of lung cancer and a 12% decreased risk of lung cancer mortality <https://bit.ly/3ixJAND>

Cite this article as: Li G, Zhang X, Liu Y, *et al.* Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. *Eur Respir J* 2022; 59: 2101399 [DOI: 10.1183/13993003.01399-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org

Received: 18 May 2021
Accepted: 14 July 2021

Abstract

Background Research on glucosamine shows anti-inflammatory and anti-cancer benefits with minimal adverse effects. We aimed to explore the relationship between use of glucosamine and risk of lung cancer and lung cancer mortality based on data from the large-scale nationwide prospective UK Biobank cohort study.

Methods Participants were enrolled between 2006 and 2010 and followed-up to 2020. The Cox proportional hazards model was used to assess the relationship between glucosamine use and risk of lung cancer and lung cancer mortality. Subgroup analyses and sensitivity analyses were performed to explore the potential effect modifications and the robustness of the main findings.

Results 439 393 participants (mean age 56 years; 53% females) with a mean follow-up of 11 years were included for analyses. 82 603 (18.80%) participants reported regular use of glucosamine at baseline. During follow-up, 1971 (0.45%) lung cancer events were documented. Glucosamine use was significantly associated with a decreased risk of lung cancer (hazard ratio (HR) 0.84, 95% CI 0.75–0.92; $p < 0.001$) and lung cancer mortality (HR 0.88, 95% CI 0.81–0.96; $p = 0.002$) in fully adjusted models. A stronger association between glucosamine use and decreased lung cancer risk was observed in participants with a family history of lung cancer when compared with those without a family history.

Conclusion Regular use of glucosamine was significantly related with decreased risk of lung cancer and lung cancer mortality, based on data from this nationwide prospective cohort study.